Clinical Trials
21 trialsNCT02727803 2026-05-22
Personalized NK Cell Therapy in CBT
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT05794880 2026-05-13
MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing
Medical College of Wisconsin
Phase NA Recruiting
NCT03934372 2026-04-16
Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
Incyte Corporation
Phase 1/2 Recruiting
NCT06368414 2026-04-02
AsterA
Korean Society of Hematology
Phase 2 Recruiting
NCT05304377 2026-04-01
CML
Enliven Therapeutics
Phase 1 Recruiting
NCT07020533 2026-03-27
A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
City of Hope Medical Center
Phase 1 Recruiting
NCT05143840 2026-03-23
ALERTCML
Augusta University
Phase 2 Recruiting
NCT06229860 2026-03-10
Impact of Personality on Adherence to Tyrosine Kinase Inhibitor Therapy in Pts w/Chronic Myeloid Leukemia
University of California, Irvine
Recruiting
NCT01746836 2026-03-09
Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06082804 2026-03-04
IPA-LMC
Centre Hospitalier Henri Duffaut - Avignon
Phase NA Recruiting
NCT05007873 2026-02-18
ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06163430 2026-01-12
CARDINAL
Terns, Inc.
Phase 1/2 Recruiting
NCT04838041 2025-07-30
Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation
Medical College of Wisconsin
Phase 2 Recruiting
NCT00935090 2025-07-08
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Barbara Ann Karmanos Cancer Institute
Recruiting
NCT06409936 2025-07-08
PEARL
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 2 Recruiting
NCT06787144 2025-07-01
CML
Enliven Therapeutics
Phase 1 Recruiting
NCT01137825 2025-06-25
Registry of Older Patients With Cancer
UNC Lineberger Comprehensive Cancer Center
Recruiting
NCT06119269 2025-06-05
PHOENICS
University of Pisa
Recruiting
NCT06423911 2025-06-03
POLARIS-2
Ascentage Pharma Group Inc.
Phase 3 Recruiting
NCT03459534 2024-10-28
A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs
Il-Yang Pharm. Co., Ltd.
Phase 3 Recruiting
NCT05367700 2023-01-13
A Study of HS-10382 in Patients With Chronic Myeloid Leukemia.
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 1 Recruiting